Yamamoto, Y., Tsunedomi, R., Fujita, Y., Otori, T., Ohba, M., Kawai, Y., . . . Matsuyama, H. (2018). Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma. Oncotarget.
Citação norma ChicagoYamamoto, Yoshiaki, et al. "Pharmacogenetics-based Area-under-curve Model Can Predict Efficacy and Adverse Events From Axitinib in Individual Patients With Advanced Renal Cell Carcinoma." Oncotarget 2018.
MLA引文Yamamoto, Yoshiaki, et al. "Pharmacogenetics-based Area-under-curve Model Can Predict Efficacy and Adverse Events From Axitinib in Individual Patients With Advanced Renal Cell Carcinoma." Oncotarget 2018.
警告：這些引文格式不一定是100％准確.